A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy…
News
While the best described cancer mutations are in regions that provide instructions to make proteins, most mutations actually happen in the noncoding regions of our…
Updated clinical trial data show that selinexor added to standard therapies can benefit multiple myeloma patients who have failed multiple prior lines of therapy, Karyopharm…
Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of the immune system being developed…
Adaptive Biotechnologies is collaborating with Sanofi to use its clonoSEQ Assay for measuring minimal residual disease in multiple myeloma patients receiving isatuximab, a treatment…
Janssen recently initiated a Phase 1b/2 clinical development program to evaluate JNJ-68284528, a chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment  of…
Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of…
Combining Aplidin (plitidepsin) with dexamethasone significantly extends their survival in heavily pretreated multiple myeloma patients compared to dexamethasone alone, data from a Phase 3 trial…
Most U.S. residents are unaware there are shortages in the availability of cancer drugs, such as those for multiple myeloma, a type of cancer…
A combination of Idera Pharmaceuticals’s treatment candidate tilsotolimod plus Yervoy (ipilimumab) is able to reduce tumors in a group of patients with refractory…
